natgillin/translations-raw huggingface dataset:
In a study of 49 adult patients with rheumatoid arthritis treated with Enbrel, there was no evidence of depression of delayed-type hypersensitivity, depression of immunoglobulin levels, or change in enumeration of effector cell populations. 
Študija pri 49 odraslih bolnikih z revmatoidnim artritisom ni pokazala, da bi zdravljenje z zdravilom Enbrel zmanjšalo zapoznelo preobčutljivostno reakcijo, zmanjšalo raven imunoglobulinov ali spremenilo število efektorskih celic.
In studies when adult patients received concurrent treatment with Enbrel plus anakinra, a higher rate of serious infections compared to Enbrel alone was observed and 2% of patients (3/139) developed neutropenia (absolute neutrophil count < 1000/mm3). 
V študijah, v katerih so odrasli bolniki sočasno prejemali zdravilo Enbrel in anakinro, so opažali večjo stopnjo resnih okužb v primerjavi s samim zdravilom Enbrel in pri 2 % bolnikov (3/139) se je pojavila nevtropenija (absolutna koncentracija nevtrofilcev < 1.000/mm
-------Enbrel----- 
--------Zdravilo Enbrel-------
If any of the following happen to the child, do not give the child more Enbrel. 
Če se pri otroku pojavi karkoli od naslednjega, mu zdravila Enbrel ne smete več dajati.
Taking into account the PRAC Assessment Report on the PSUR(s) for etanercept (except for biosimilars), the scientific conclusions of CHMP are as follows: 
Upoštevajoč poročilo Odbora za oceno tveganja na področju farmakovigilance (PRAC) o oceni rednih posodobljenih poročil o varnosti zdravila (PSUR) za etanercept (razen podobnih bioloških zdravil) je Odbor za zdravila za uporabo v humani medicini (CHMP) sprejel naslednje znanstvene zaključke:
Enbrel has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease. 
Ugotovili so, da zdravilo Enbrel izboljša telesno funkcijo pri bolnikih s psoriatičnim artritisom in upočasni hitrost napredovanja okvar perifernih sklepov, merjenih z rentgenskim slikanjem, pri bolnikih s poliartikularnimi simetričnimi podvrstami bolezni.
h. Disposing of supplies 
h. Odstranjevanje odpadkov
Whether used alone or in combination with methotrexate, Enbrel can slow down the damage to your joints caused by the rheumatoid arthritis and improve your ability to do normal daily activities. 
Zdravilo Enbrel samo ali v kombinaciji z metotreksatom lahko upočasni razvoj poškodb v sklepih zaradi revmatoidnega artritisa in izboljša sposobnost opravljanja vsakodnevnih opravil.
Enbrel 25 mg was significantly superior to methotrexate for erosion scores at both 12 and 24 months. 
Učinek 25 mg odmerka zdravila Enbrel je bil pomembno boljši kot pri metotreksatu glede ocene erozije sklepov, tako po 12 kot po 24 mesecih.
In study 3, the majority of patients (77%) who were initially randomised to 50 mg twice weekly and had their Enbrel dose decreased at week 12 to 25 mg twice weekly maintained their PASI 75 response through week 36. 
V šudiji 3 je večina bolnikov (77 %), ki so bili uvodoma randomizirani na 50 mg dvakrat na teden in so jim odmerek zdravila Enbrel po 12 tednih znižali na 25 mg dvakrat na teden, odziv PASI 75 ohranila do 36. tedna.
Significant advantages for Enbrel in combination with methotrexate compared with Enbrel monotherapy and methotrexate monotherapy were also observed after 24 months. 
Pomembne prednosti zdravila Enbrel v kombinaciji z metotreksatom pred monoterapijo z zdravilom Enbrel ali monoterapijo z metotreksatom so ugotovili tudi po 24 mesecih.
• Make sure your syringe does not contain any air bubbles. 
Prepričajte se, da v brizgi ni zračnih mehurčkov.
In the toxicological studies with Enbrel, no dose-limiting or target organ toxicity was evident. 
V študijah toksičnosti zdravila Enbrel ni bilo opaziti toksičnosti, ki bi omejevala odmerjanje, niti toksičnosti za tarčne organe.
Opportunistic infections have been reported in association with Enbrel, including invasive fungal, parasitic (including protozoal), viral (including herpes zoster), bacterial (including Listeria and Legionella), and atypical mycobacterial infections. 
V povezavi z zdravilom Enbrel so poročali o oportunističnih okužbah, vključno z invazivnimi glivičnimi, parazitskimi (vključno s protozojskimi), virusnimi (vključno s herpesom zoster), bakterijskimi (vključno z bakterijama Listeria in Legionella) in atipičnimi mikobakterijskimi okužbami.
In clinical studies, concurrent administration of abatacept and Enbrel resulted in increased incidences of serious adverse events. 
V kliničnih študijah je sočasna uporaba abatacepta in zdravila Enbrel zvečala pojavnost resnih neželenih učinkov.
The dosage of Enbrel is based on body weight for paediatric patients. 
Odmerjanje zdravila Enbrel za pediatrične bolnike temelji na njihovi telesni masi.
The combination Enbrel and anakinra has not demonstrated increased clinical benefit, and is therefore not recommended. 
Ni dokazano, da bi bila kombinacija zdravila Enbrel in anakinre klinično koristnejša, zato ni priporočljiva.
After the 12-week double-blind treatment period, all patients received Enbrel 0.8 mg/kg (up to 50 mg) once weekly for additional 24 weeks. 
Po 12-tedenskem obdobju dvojno slepega zdravljenja so vsi bolniki prejemali zdravilo Enbrel v odmerku 0,8 mg/kg (do 50 mg) enkrat na teden še dodatnih 24 tednov.
Clinical improvement, including onset of action within 2 weeks with Enbrel 25 mg, was similar to that seen in the previous trials and was maintained for up to 24 months. 
Klinično izboljšanje, vključno z nastopom delovanja zdravila v 2 tednih pri 25 mg zdravila Enbrel, je bilo podobno tistemu, ki so ga ugotavljali v prejšnjih preskušanjih, in se je ohranjalo do 24 mesecev.
Enbrel is administered by an injection under the skin (by subcutaneous injection). 
Zdravilo Enbrel se injicira pod kožo (subkutano injiciranje).
Enbrel, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function. 
Dokazali so, da zdravilo Enbrel samo ali v kombinaciji z metotreksatom upočasni hitrost napredovanja poškodb sklepov, merjenih z rentgenskim slikanjem, in izboljša telesno funkcijo.
In addition, in a double-blind, placebo-controlled trial in adult patients receiving background methotrexate, patients treated with Enbrel and anakinra were observed to have a higher rate of serious infections (7%) and neutropenia than patients treated with Enbrel (see sections 4.4 and 4.8). 
Poleg tega so v dvojno slepem, s placebom nadzorovanem preskušanju pri odraslih bolnikih, ki so prejemali tudi metotreksat, opazili, da so imeli bolniki, zdravljeni z zdravilom Enbrel in anakinro, večjo stopnjo resnih okužb (7 %) in nevtropenije kot bolniki, zdravljeni z zdravilom Enbrel (glejte poglavji 4.4 in 4.8).
After you have withdrawn the Enbrel from the vial, you may have some air in the syringe. 
Po tem, ko ste potegnili zdravilo Enbrel iz viale, je možno, da je v brizgo prišlo tudi nekaj zraka.
Step 1: Preparing for an Enbrel injection Step 2: Choosing an injection site Step 3: Injecting the Enbrel solution Step 4: Disposing of the used MYCLIC pen 
Korak 1: Priprava na injiciranje zdravila Enbrel Korak 2: Izbira mesta injiciranja Korak 3: Injiciranje raztopine zdravila Enbrel Korak 4: Odstranjevanje uporabljenega peresnika MYCLIC
Approximately 15% of subjects who received Enbrel achieved an ACR 70 response at month 3 and month 6 compared to fewer than 5% of subjects in the placebo arm. 
Približno 15 % bolnikov, zdravljenih z zdravilom Enbrel, je do 3. in 6. meseca doseglo odziv ACR 70, v primerjavi z manj kot 5 % tistih, ki so prejemali placebo.
The double-blind period was followed by an open-label period during which all patients receive Enbrel 50 mg weekly for up to an additional 92 weeks. 
Dvojno slepemu obdobju je sledilo odprto obdobje, med katerim so vsi bolniki prejemali zdravilo Enbrel v odmerku 50 mg na teden, kar je trajajo do 92 dodatnih tednov.
Adding solvent e. 
Dodajanje vehikla e.
Serious allergic/anaphylactic react ions (including angioedema, bronchospasm), sarcoidosis 
resne alergijske/ anafilaktične reakcije (vključno z angioedemom in bronhospazmom), sarkoidoza poslabšanje simptomov dermatomiozitisa
Adult patients treated with Enbrel and anakinra were observed to have a higher rate of serious infection when compared with patients treated with either Enbrel or anakinra alone (historical data). 
Pri odraslih bolnikih, zdravljenih z zdravilom Enbrel in anakinro, so opazili večjo stopnjo resnih okužb kot pri bolnikih, zdravljenih samo z zdravilom Enbrel ali samo z anakinro (retrospektivni podatki).
There have been rare reports of CNS demyelinating disorders in patients treated with Enbrel (see section 4.8). 
Poročali so o redkih primerih demielinizirajočih obolenj centralnega živčnega sistema (CŽS) pri bolnikih, zdravljenih s tem zdravilom (glejte poglavje 4.8).
In clinical studies conducted for more than 2 years with 351 ankylosing spondylitis patients, 6 malignancies were reported in Enbrel-treated patients. 
V kliničnih študijah z zdravilom Enbrel, ki so trajale več kot 2 leti in so vključevale 351 bolnikov z ankilozirajočim spondilitisom, so poročali o 6 primerih malignega obolenja.
In subjects treated with approved doses of etanercept in clinical trials for up to 12 months, cumulative rates of anti-etanercept antibodies were approximately 6% of subjects with rheumatoid arthritis, 7.5% of subjects with psoriatic arthritis, 2% of subjects with ankylosing spondylitis, 7% of subjects with psoriasis, 9.7% of subjects with paediatric psoriasis, and 4.8 % of subjects with juvenile idiopathic arthritis. 
Pri bolnikih, ki so jih v kliničnih preskušanjih zdravili z etanerceptom v odobrenih odmerkih do 12 mesecev, je bila kumulativna pogostnost protiteles proti etanerceptu približno 6 % pri bolnikih z revmatoidnim artritisom, 7,5 % pri bolnikih s psoriatičnim artritisom, 2 % pri bolnikih z ankilozirajočim spondilitisom, 7 % pri bolnikih s psoriazo, 9,7 % pri bolnikih z otroško psoriazo in 4,8 % pri bolnikih z juvenilnim idiopatskim artritisom.
Instead, the safety and efficacy of Enbrel were assessed in four randomised, double-blind, placebo-controlled studies. 
Namesto tega so varnost in učinkovitost zdravila Enbrel ocenili v štirih randomiziranih, dvojno slepih, s placebom nadzorovanih študijah.
• Take the ENBREL vial out of the refrigerator and place it on a flat surface. 
Vzemite vialo zdravila ENBREL iz hladilnika in jo postavite na ravno površino.
The safety and efficacy of Enbrel were assessed in a two-part study in 69 children with polyarticularcourse juvenile idiopathic arthritis who had a variety of juvenile idiopathic arthritis onset types (polyarthritis, pauciarthritis, systemic onset). 
Varnost in učinkovitost zdravila Enbrel je bila ugotovljena v dvodelni študiji pri 69 otrocih s poliartikularnim potekom juvenilnega idiopatskega artritisa z različnimi tipi nastopa bolezni (poliartritis, oligoartritis, sistemski nastop).
Patients weighing less than 62.5 kg should be accurately dosed on a mg/kg basis using the powder and solvent for solution for injection presentations or the powder for solution for injection presentations (see below for dosing for specific indications). 
Bolnikom, ki tehtajo manj kot 62,5 kg, je treba odmerek natančno izračunati na podlagi mg/kg in uporabiti zdravilo Enbrel v obliki praška in vehikla za raztopino za injiciranje ali praška za raztopino za injiciranje (za odmerjanje pri specifičnih indikacijah glejte nadaljevanje).
b. One cotton ball or gauze 3. 
b. Eno vato ali gazo.
When you do this, if you accidentally push liquid back into the vial, slowly pull the plunger to draw the liquid back into the syringe. 
Če pri tem v vialo iztisnete tudi raztopino, morate bat ponovno počasi izvleči, da raztopino povlečete nazaj v brizgo.
ACR 20 Month 3 
ACR 20 3. mesec b
The percentage of patients who developed new positive anti-double-stranded DNA antibodies was also higher by radioimmunoassay (15% of patients treated with Enbrel compared to 4% of placebo-treated patients) and by Crithidia luciliae assay (3% of patients treated with Enbrel compared to none of placebo-treated patients). 
Tudi odstotek bolnikov, ki so razvili nova pozitivna avtoprotitelesa proti dvojno vijačni DNK, je bil večji, merjeno z radioimunskimi testi (15 % pri zdravilu Enbrel in 4 % pri placebu) in s testom na Crithidia luciliae (3 % pri zdravilu Enbrel in 0 % pri placebu).
In the Phase 3 studies in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, no overall differences in adverse events, serious adverse events, and serious infections in patients age 65 or older who received Enbrel were observed compared with younger patients. 
V študijah 3. faze pri revmatoidnem artritisu, psoriatičnem artritisu in ankilozirajočem spondilitisu pri bolnikih, starih 65 let ali več, ki so prejeli zdravilo Enbrel, na splošno niso opazili nobenih razlik glede neželenih učinkov, resnih neželenih učinkov in resnih okužb v primerjavi z mlajšimi bolniki.
Undesirable effects in paediatric patients with juvenile idiopathic arthritis 
Neželeni učinki pri otrocih z juvenilnim idiopatskim artritisom
One hundred and twelve (112) patients were randomised to receive a dose of 25 mg of Enbrel (n=57) or placebo (n=55) twice a week for 24 weeks. 
Randomizirali so sto dvanajst (112) bolnikov, ki so 24 tednov dvakrat na teden dobivali 25 mg odmerek zdravila Enbrel (n = 57) ali placebo (n = 55).
In the 2-year active-controlled study where patients were treated with either Enbrel alone, methotrexate alone or Enbrel in combination with methotrexate, the rates of serious infections were similar among the treatment groups. 
V dveletni študiji, nadzorovani z učinkovino, v kateri so bili bolniki zdravljeni z zdravilom Enbrel, metotreksatom ali kombinacijo zdravila Enbrel in metotreksata, je bila stopnja pogostnosti resnih okužb v treh skupinah podobna.
Malignancies, some fatal, have been reported among children, adolescents and young adults (up to 22 years of age) treated with TNF-antagonists (initiation of therapy ≤ 18 years of age), including Enbrel, in the postmarketing setting. 
Pri otrocih, mladostnikih in mladih odraslih (do 22. leta starosti), ki so se zdravili z antagonisti TNF (začetek zdravljenja ≤ 18 let), vključno z zdravilom Enbrel, so v obdobju trženja poročali o malignostih, med katerimi so bile tudi smrtne.
• Vaccinations: If possible, children should be up to date with all vaccinations before using Enbrel. 
• Cepljenja: Najbolje je, da otrok pred začetkom zdravljenja z zdravilom Enbrel opravi vsa predvidena cepljenja.
Concurrent administration of Enbrel and anakinra has been associated with an increased risk of serious infections and neutropenia compared to Enbrel alone. 
Sočasna uporaba zdravila Enbrel in anakinre je bila povezana s povečanim tveganjem za pojav resnih okužb in nevtropenije v primerjavi z zdravljenjem samo z zdravilom Enbrel.
Enbrel treatment should be initiated and supervised by specialist physicians experienced in the diagnosis and treatment of juvenile idiopathic arthritis or paediatric plaque psoriasis. 
Zdravljenje z zdravilom Enbrel lahko uvede in nadzoruje le zdravnik specialist, ki ima izkušnje z diagnosticiranjem in zdravljenjem juvenilnega idiopatskega artritisa ali otroške psoriaze v plakih.
Serious infections experienced by Enbrel-treated patients included cellulitis, gastroenteritis, pneumonia, cholecystitis, osteomyelitis, gastritis, appendicitis, Streptococcal fasciitis, myositis, septic shock, diverticulitis and abscess. 
Med resnimi okužbami pri bolnikih, zdravljenih z zdravilom Enbrel, so bile celulitis, gastroenteritis, pljučnica, holecistitis, osteomielitis, gastritis, apendicitis, streptokokni fasciitis, miozitis, septični šok, divertikulitis in absces.
ACR 20 and 50 responses were higher in patients treated with Enbrel at 3 and 6 months than in patients treated with placebo (ACR 20: Enbrel 62% and 59%, placebo 23% and 11% at 3 and 6 months respectively: ACR 50: Enbrel 41% and 40%, placebo 8% and 5% at months 3 and 6, respectively; p<0.01 Enbrel vs placebo at all timepoints for both ACR 20 and ACR 50 responses). 
Odstotek bolnikov, ki so po 3 oziroma 6 mesecih dosegli odziv ACR 20 ali ACR 50, je bil v skupini bolnikov, ki so bili zdravljeni z zdravilom Enbrel, večji kot pri bolnikih, ki so prejemali placebo (ACR 20 po 3 oz. 6 mesecih: zdravilo Enbrel 62 % oz. 59 %, placebo 23 % oz. 11 %; ACR 50 po 3 oz. 6 mesecih: zdravilo Enbrel 41 % oz. 40 %, placebo 8 % oz. 5 %; p < 0,01 za zdravilo Enbrel proti placebu v vseh časovnih točkah, tako za odziv ACR 20 kot za odziv ACR 50).
All patients and parents/caregivers should be advised that if the patient develops signs and symptoms suggestive of blood dyscrasias or infections (e.g., persistent fever, sore throat, bruising, bleeding, paleness) whilst on Enbrel, they should seek immediate medical advice. 
Vse bolnike in starše/skrbnike je treba opozoriti, da morajo pri bolniku v primeru pojava znakov ali simptomov, ki kažejo na krvno diskrazijo ali okužbo (npr. trdovratna zvišana telesna temperatura, vnetje žrela, podplutbe, krvavitve, bledica), med zdravljenjem s tem zdravilom takoj poiskati zdravniško pomoč.
In the double-blind period, patients received Enbrel 50 mg weekly or placebo for 12 weeks. 
V dvojno slepem obdobju so bolniki prejemali zdravilo Enbrel v odmerku 50 mg na teden ali placebo 12 tednov.
Gently tap the syringe to make any bubbles rise to the top of the syringe, near the needle (see Diagram 8). 
Rahlo potrkajte po brizgi, da se bodo mehurčki dvignili na vrh brizge, v bližino igle (glejte sliko 8).
Patients in the Enbrel in combination with methotrexate therapy group had significantly higher ACR 20, ACR 50, ACR 70 responses and improvement for DAS and HAQ scores at both 24 and 52 weeks than patients in either of the single therapy groups (results shown in table below). 
Pri bolnikih, ki so prejemali zdravilo Enbrel v kombinaciji z metotreksatom, so bili odzivi ACR 20, ACR 50 in ACR 70 ter izboljšanja na lestvicah ocene stopnje bolezni (DAS - Disease Activity Score) in HAQ tako po 24 kot po 52 tednih statistično pomembno večji kot pri bolnikih, ki so jih zdravili z enim samim zdravilom (izsledki so povzeti v spodnji preglednici).
A single 50 mg/ml injection of Enbrel was found to be bioequivalent to two simultaneous injections of 25 mg/ml. 
Enkratna injekcija zdravila Enbrel v odmerku 50 mg/ml je bioekvivalentna dvema sočasnima injekcijama po 25 mg/ml.
Instructions for preparing and giving an injection of Enbrel 
Navodila za pripravo in dajanje injekcije zdravila Enbrel
In a polyarticular-course juvenile idiopathic arthritis trial with Enbrel, 69 patients (aged 4 to 17 years) were administered 0.4 mg Enbrel/kg twice weekly for three months. 
V kliničnem preskušanju pri 69 bolnikih s poliartikularnim potekom juvenilnega idiopatskega artritisa, starih od 4 do 17 let, so injicirali 0,4 mg zdravila Enbrel/kg 2-krat tedensko v obdobju treh mesecev.
ACR 70 Month 3 
ACR 70 3. mesec b
Preparing the Enbrel dose for injection d. 
Priprava odmerka zdravila Enbrel za injiciranje d.
• With the needle still inserted in the vial, check the syringe for air bubbles. 
Ko je igla še vedno v viali, preverite, ali so v brizgi zračni mehurčki.
Gently move the vial in circles a few times, to dissolve the powder (see Diagram 6). 
Nekajkrat nežno krožno zavrtite vialo, da se prašek raztopi (glejte sliko 6).
Enbrel is administered by subcutaneous injection. 
Zdravilo Enbrel se daje s subkutano injekcijo.
At week 104, the mean change from baseline in the SPARCC score measured on MRI for all Enbrel-treated subjects was 4.64 for the SIJ (n=153) and 1.40 the spine (n=154). 
Pri vseh bolnikih, ki so prejemali zdravilo Enbrel, je po 104 tednih povprečna sprememba od izhodišča za rezultat SPARCC, merjen z magnetnoresonančnim slikanjem, znašala 4,64 za SIJ (n = 153) in 1,40 za hrbtenico (n = 154).
All subdomains of the HAQ were improved in patients treated with Enbrel compared to controls at 3 and 6 months. 
Po vseh kriterijih vprašalnika HAQ je bilo vidno izboljšanje pri bolnikih na zdravilu Enbrel v 3. in 6. mesecu zdravljenja v primerjavi s kontrolno skupino.
• Inspect the expiry dates on both the Enbrel vial label and the water for injections. 
Preverite rok uporabnosti na nalepki viale zdravila Enbrel in vode za injekcije.
Step 1: Setting up for an injection Step 2: Choosing an injection site Step 3: Injecting the Enbrel solution Step 4: Disposing of supplies 
Korak 1: Priprava na injiciranje Korak 2: Izbira mesta injiciranja Korak 3: Injiciranje raztopine zdravila Enbrel Korak 4: Odstranjevanje odpadkov
All patients should be informed to seek medical advice if signs/symptoms suggestive of tuberculosis (e.g., persistent cough, wasting/weight loss, low-grade fever) appear during or after Enbrel treatment. 
Vsem bolnikom je treba naročiti, naj poiščejo zdravniško pomoč, če se med zdravljenjem z zdravilom Enbrel ali po njem pojavijo znaki/simptomi, ki kažejo na tuberkulozo (npr. trdovraten kašelj, hiranje/hujšanje, nekoliko zvišana telesna temperatura).
At week 12, there was a statistically significant improvement in the SPARCC (Spondyloarthritis Research Consortium of Canada) score for the sacroiliac joint (SIJ) as measured by MRI for patients receiving Enbrel. 
Pri bolnikih, ki so prejemali zdravilo Enbrel, je po 12 tednih prišlo do statistično pomembnega izboljšanja rezultata SPARCC (SPARCC - Spondyloarthritis Research Consortium of Canada; Kanadski konzorcij za raziskovanje spondilartritisa) za sakroiliakalni sklep (SIJ - Sacroiliac Joint), ki so ga merili z magnetnoresonančnim slikanjem.
There have been reports of inflammatory bowel disease and uveitis in JIA patients being treated with Enbrel from post-marketing sources, including a very small number of cases indicating a positive rechallenge (see section 4.4). 
Viri iz obdobja trženja so poročali o kronični vnetni črevesni bolezni in uveitisu pri bolnikih z JIA, ki so se zdravili z zdravilom Enbrel, vključno z zelo majhnim številom primerov, ki kažejo na ponoven pojav bolezni ob naslednjem dajanju zdravila (glejte poglavje 4.4).
Enbrel treatment should be initiated and supervised by specialist physicians experienced in the diagnosis and treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, plaque psoriasis or paediatric plaque psoriasis. 
Zdravljenje z zdravilom Enbrel lahko uvede in nadzoruje le zdravnik specialist, ki ima izkušnje z diagnosticiranjem in zdravljenjem revmatoidnega artritisa, juvenilnega idiopatskega artritisa, psoriatičnega artritisa, ankilozirajočega spondilitisa, radiografsko nezaznavnega aksialnega spondilartritisa, psoriaze v plakih ali otroške psoriaze v plakih.
• Infections/surgery: If the child develops a new infection, or is about to have any major surgery, the doctor may wish to monitor the child's treatment with Enbrel. 
Okužbe/operacije: Če se pri otroku pojavi nova okužba ali če je pri otroku predvidena kakršnakoli večja operacija, bo zdravnik morda želel spremljati zdravljenje z zdravilom Enbrel.
When the syringe is empty, pull the needle out of the skin, being careful to keep it at the same angle as inserted. 
Ko je brizga prazna, izvlecite iglo iz kože pod istim kotom, kot ste jo zabodli vanjo.
Hepat it is B reactivation, listeria 
reaktivacija hepatitisa B, listerija
(n = 231) a: Patients who did not complete 12 months in the study were considered to be non-responders. 
v izhodišču po 52 tednih a: Bolniki, ki v študiji niso sodelovali 12 mesecev, so bili obravnavani kot neodzivni.
Choosing an injection site g. 
Izbira mesta injiciranja h.
If you forget a dose, you should inject it as soon as you remember, unless the next scheduled dose is the next day; in which case you should skip the missed dose. 
Če ste na predvideni odmerek zdravila Enbrel pozabili, ga morate injicirati takoj, ko se spomnite, razen če je naslednji odmerek predviden za naslednji dan.
Diagram 1 The MYCLIC pre-filled pen 
Slika 1 Napolnjeni peresnik MYCLIC